Psychedelics: Safety and Efficacy.
International Journal of Environmental Research and Public Health January 21, 2025 DOI: 10.3390/ijerph22020134 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Psychedelic-assisted therapy |
| Keywords | Mental health treatment Clinical research Psychiatric medicine |
| Citations | 1 |
| Key findings | Existing psychedelic research often lacks scientific rigor and fails to adequately address safety and efficacy, while personal and financial biases further compromise the field. |
Abstract
Psychedelic research has experienced a renaissance in recent years, with many researchers exploring the possible therapeutic effects of these drugs. Medical institutions, universities, pharmaceutical companies, and governmental institutions alike have been showing an increase in support of this research, as shown through the recent establishment of various psychedelic research facilities across the United States. However, the safety and efficacy of psychedelic usage are not the focus of the existing research. Additionally, many of the studies on psychedelic use that have already been published lack the necessary scientific rigor required for studies of such medical importance. The current paper will discuss the issue of misleading information as well as poorly designed studies and what implications these have on the rescheduling of psychedelic drugs that are currently categorized as Schedule I. The current Schedule I status of psychedelics means that they are considered to have no legitimate medical value as well as a high potential for abuse. Furthermore, the current paper aims to discuss psychedelics while drawing awareness to the lack of the literature surrounding the safety and efficacy of psychedelics for medical use. This paper will also discuss the history of psychedelic use and abuse, the adverse effects of psychedelic use, and the role that personal and financial bias has within the psychedelic research field.
Comparable studies
Other narrative reviews on psychedelic-assisted therapy, most cited first.
Citations in the library
Cites 26
- Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial Psychological Medicine June 15, 2018
- A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders JAMA Psychiatry March 1, 2017
- Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences Journal of Psychopharmacology August 31, 2016
- Single-Dose Psilocybin Treatment for Major Depressive Disorder JAMA August 31, 2023
- Increased global integration in the brain after psilocybin therapy for depression. Nature Medicine April 11, 2022
and 21 more in the library